MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
7.83
+0.07
+0.90%
Closed 19:31 04/28 EDT
OPEN
7.95
PREV CLOSE
7.76
HIGH
8.16
LOW
7.68
VOLUME
53.42K
TURNOVER
--
52 WEEK HIGH
49.27
52 WEEK LOW
5.35
MARKET CAP
27.56M
P/E (TTM)
-0.4016
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TPST last week (0421-0425)?
Weekly Report · 23h ago
Tempest Therapeutics announces FDA granted ODD to TPST-1495
TipRanks · 04/21 12:08
TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR TPST-1495 TO TREAT PATIENTS WITH FAP
Reuters · 04/21 12:00
TEMPEST THERAPEUTICS INC - DATA FROM PHASE 2 STUDY EXPECTED IN 2026
Reuters · 04/21 12:00
TEMPEST THERAPEUTICS INC - PHASE 2 STUDY OF TPST-1495 IN FAP PATIENTS TO BEGIN THIS YEAR
Reuters · 04/21 12:00
Weekly Report: what happened at TPST last week (0414-0418)?
Weekly Report · 04/21 11:45
TEMPEST THERAPEUTICS INC - MAJORITY OF COSTS TO BE INCURRED IN Q2 2025 - SEC FILING
Reuters · 04/18 20:20
Weekly Report: what happened at TPST last week (0407-0411)?
Weekly Report · 04/14 11:33
More
About TPST
More
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Recently
Symbol
Price
%Change

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.